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Background: Case series and a post hoc subgroup analysis of a large randomized trial have suggested a
potential benefit in treating ruptured abdominal aortic aneurysms (rAAAs) using endovascular aneurysm
repair (EVAR)with local anaesthesia (LA) rather than general anaesthesia (GA). The uptake and outcomes
of LA in clinical practice remain unknown.
Methods: The UK National Vascular Registry was interrogated for patients presenting with rAAA
managed with EVAR under different modes of anaesthesia between 1 January 2014 and 31 December
2016. The primary outcome was in-hospital mortality. Secondary outcomes included: the number of
centres performing EVAR under LA; the proportion of patients receiving this technique; duration of
hospital stay; and postoperative complications.
Results: Some 3101 patients with rAAA were treated in 72 hospitals during the study: 2306 underwent
on open procedure and 795 had EVAR (LA, 319; GA, 435; regional anaesthesia, 41). Overall, 56 of 72
hospitals (78 per cent) offered LA for EVAR of rAAA. Baseline characteristics and morphology were
similar across the three EVAR subgroups. Patients who had surgery under LA had a lower in-hospital
mortality rate than patients who received GA (59 of 319 (18⋅5 per cent) versus 122 of 435 (28⋅0 per cent)),
and this was unchanged after adjustment for factors known to influence survival (adjusted hazard ratio
0⋅62, 95 per cent c.i. 0⋅45 to 0⋅85; P= 0⋅003). Median hospital stay and postoperative morbidity from other
complications were similar.
Conclusion: The use of LA for EVAR of rAAA has been adopted widely in the UK.Mortality rates appear
lower than in patients undergoing EVAR with GA.
Paper accepted 9 July 2018
Published online in Wiley Online Library (www.bjs.co.uk). DOI: 10.1002/bjs.10973
Introduction
Without emergency surgical intervention, ruptured
abdominal aortic aneurysm (rAAA) is usually fatal. Global
experience with endovascular aneurysm repair (EVAR) for
elective abdominal aortic aneurysm (AAA) has led to its
increasing use in the emergency setting1,2. Comparative
outcomes between conventional open and endovascular
repair for ruptured AAA (rEVAR) have been assessed in one
case series3 and four RCTs4–7. A recent individual-patient
meta-analysis8 of three RCTs that compared EVAR with
open repair for rAAA reported that women might ben-
efit more from the EVAR approach and that patients
are discharged sooner after EVAR, although survival
at 90 days was similar in the two groups. Despite this,
earlier discharge from critical care, shorter hospital
stay, and a higher proportion discharged directly home
in the EVAR group means that the EVAR approach
is likely to gain further support for its use in rAAA,
especially in specialist centres. Furthermore, the EVAR
approach for rAAA may allow treatment of more elderly
patients and those with significant co-morbidities who
would not be considered feasible candidates for open
surgery2.
A case series3 of 20 patients, published in 2002, demon-
strated the feasibility of performing rEVAR under local
anaesthesia (LA). A subsequent post hoc subgroup analysis
of a cohort of 186 patients who underwent rEVAR in the
IMPROVE (Immediate Management of the Patient with
Rupture: Open Versus Endovascular repair) trial9 demon-
strated a significantly reduced 30-day mortality rate for
patients operated on under LA compared with surgery
© 2018 The Authors. BJS published by John Wiley & Sons Ltd on behalf of BJS Society Ltd. BJS
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in
any medium, provided the original work is properly cited and is not used for commercial purposes.
R. Mouton, C. A. Rogers, R. A. Harris and R. J. Hinchliffe
under general anaesthesia (GA): odds ratio 0⋅27 (95 per
cent c.i. 0⋅10 to 0⋅70), after adjustment for potential con-
founding. The magnitude of benefit observed with LA in
the IMPROVE trial warrants further investigation and, if
replicated in a well conducted RCT, would suggest that
LA should become the standard of care in rEVAR. How-
ever, at this stage little is known about how applicable this
technique might be to patients in everyday clinical prac-
tice and how widely the technique has been adopted across
the UK.
The UK National Vascular Registry (NVR), which cap-
tures data on more than 90 per cent of AAA procedures,
provides a unique opportunity to examine practice and
outcomes in a real-world setting, and includes centres
that may not have contributed patients to the IMPROVE
trial7,9,10. The aim of this study was to quantify the
uptake of LA for rEVAR across all UK vascular centres
and evaluate whether the benefit of LA observed in the
IMPROVE trial has been replicated in everyday clinical
practice.
Methods
National Vascular Registry
The NVR was commissioned by the Healthcare Quality
Improvement Partnership (HQIP), as part of the National
Clinical Audit and Patient Outcomes Programme, to mea-
sure quality of care and outcomes in patients undergoing
vascular interventions in National Health Service (NHS)
hospitals10. Data submission is mandatory and forms part
of the revalidation of vascular surgeons. Data are assessed
for consistency, including range checks, and also com-
parison of case ascertainment with the Hospital Episode
Statistics (HES) data set, to which all NHS Trusts in
England are obliged to contribute for financial probity11.
Equivalent checks were applied to data for patients oper-
ated on in Scotland (Scottish Morbidity Record, SMR01),
Wales (Patient Episode Database for Wales) and North-
ern Ireland (Hospital Activity Statistics). The NVR is
the largest recognized register of AAA procedures in the
UK. Permission was obtained from HQIP for the NVR
Patients undergoing AAA repair between
January 2014 and December 2016
n=20 936
Patients excluded n=7582
 Open repair n=7520*
 Revision open repair n=62
Patients excluded n=2776
 Complex EVAR n=2283
 Revision EVAR n=431
 Chronic dissection n=25
 Acute dissection n=21
 Aortic transection n=15
 Unknown n=1
Patients receiving EVAR
n=13 354
Patients receiving a standard infrarenal
EVAR procedure
n=10 578
Patients excluded n=9783
 Asymptomatic n=8785
 Symptomatic unruptured n=998
Regional anaesthesia
n=41
General anaesthesia
n=435
Local anaesthesia
n=319
Patients receiving a standard infrarenal
EVAR procedure for ruptured AAA
n=795
Fig. 1 Study profile. *Of 7520 open repairs, 2306 were for ruptured abdominal aortic aneurysm (AAA). EVAR, endovascular aneurysm
repair
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Fig. 2 Use of local anaesthesia (LA) according to a median annual abdominal aortic aneurysm (AAA) caseload and b timing of
endovascular aneurysm repair (EVAR). Values are median (i.q.r.). Standard hours are defined as operation start time from 08.00 to
17.00 hours Monday to Friday. rEVAR, ruptured endovascular aneurysm repair
to release anonymized patient data under a data-sharing
agreement signed between HQIP and the University of
Bristol.
Study population
The study population comprised patients undergoing
repair of a rAAA in the UK between 1 January 2014 and
31 December 2016. The registry classifies each procedure
as open, EVAR, complex EVAR, revision open, revision
EVAR or endovascular aneurysm sealing (EVAS), and
the AAAs were grouped into asymptomatic, symptomatic
unruptured, ruptured, aortic transection, acute dissection
or chronic dissection. The EVAR and EVAS procedures
were combined. The following were excluded: aortic tran-
sections, acute and chronic dissections, thoracic aneurysms
and thoracoabdominal aneurysms. Case ascertainment for
the NVR for the period 2014–2016 was 91 per cent for
rAAA12.
Mode of anaesthesia
Modes of anaesthesia captured in the NVR include GA,
LA and regional anaesthesia (RA). The NVR does not
identify procedures that were initiated under LA only but
then converted to GA (or RA) later in the procedure. Such
procedures are coded as GA or RA, as appropriate.
Data collection
Data items included in the NVR and available for analysis
are summarized in Appendix S1 (supporting information).
The Hardman index13 for predicting the risk of an adverse
outcome is not captured in the NVR. However, four of
the five factors used to derive the index are included.
Therefore, a modified Hardman index was derived based
on age, haemoglobin, serum creatinine and ECG findings
only (excluding data on loss of consciousness).
Study outcomes
The primary outcome of this study was in-hospital mor-
tality. Hospital discharge was defined as discharge from
the hospital in which the vascular surgical procedure was
performed. Patients could be discharged home, to a refer-
ring hospital, or to a rehabilitation hospital. Secondary
clinical outcomes included postoperative length of hospital
stay (LOS), ICU admission rate, duration of ICU stay and
postoperative complications. Secondary process outcomes
included uptake of EVAR for rAAA across centres and use
of LA for these procedures.
Statistical analysis
Continuous data are summarized as mean(s.d.) values (or
median (i.q.r.) if the distribution is skewed). Categorical
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Table 1 Baseline characteristics of patients undergoing emergency endovascular aneurysm repair
LA (n=319) GA (n=435) RA (n=41)
MD (LA
versus GA)
Demographics
Age (years)* 79⋅4(8⋅2) 77⋅0(9⋅0) 79⋅9(7⋅3) 0⋅27
Sex ratio (M : F) 274 : 45 368 : 67 37 : 4 0⋅04
Smoking status
Current or stopped <2months previously 61 (19⋅1) 113 of 431 (26⋅2) 9 (22) −0⋅17
Ex-smoker 196 (61⋅4) 240 of 431 (55⋅7) 23 (56) 0⋅12
Never smoker 62 (19⋅4) 78 of 431 (18⋅1) 9 (22) 0⋅03
ASA grade
I (normal) 1 (0⋅3) 3 (0⋅7) 0 (0) −0⋅05
II (mild disease) 8 (2⋅5) 16 (3⋅7) 2 (5) −0⋅07
III (severe, not life-threatening) 41 (12⋅9) 64 (14⋅7) 12 (29) −0⋅05
IV (severe, life-threatening) 219 (68⋅7) 287 (66⋅0) 23 (56) 0⋅06
V (moribund) 50 (15⋅7) 65 (14⋅9) 4 (10) 0⋅02
AAA maximum diameter (mm)* 75⋅8(17⋅7) 72⋅8(20⋅1) 72⋅6(21⋅4) 0⋅16
Cardiovascular risk factors
Co-morbidity on admission (any) 276 (86⋅5) 386 (88⋅7) 36 (88) −0⋅07
Diabetes 42 (13⋅2) 66 (15⋅2) 5 (12) −0⋅06
Hypertension 220 (69⋅0) 285 (65⋅5) 21 (51) 0⋅07
Stroke 21 (6⋅6) 31 (7⋅1) 3 (7) −0⋅02
Ischaemic heart disease 125 (39⋅2) 177 (40⋅7) 19 (46) −0⋅03
Chronic heart failure 28 (8⋅8) 32 (7⋅4) 3 (7) 0⋅05
Chronic renal disease 55 (17⋅2) 77 (17⋅7) 11 (27) −0⋅01
Chronic lung disease 98 (30⋅7) 113 (26⋅0) 19 (46) 0⋅11
Hardman index
Age>76 years 217 (68⋅0) 262 of 434 (60⋅4) 29 (71) 0⋅16
Haemoglobin <9g/dl 20 of 152 (13⋅2) 35 of 219 (16⋅0) 3 of 12 (25) −0⋅08
Serum creatinine >190 μmol/l 29 of 318 (9⋅1) 42 of 434 (9⋅7) 3 (7) −0⋅02
Abnormal ECG 149 of 284 (52⋅5) 176 of 377 (46⋅7) 20 of 38 (53) 0⋅12
No. of Hardman factors (complete case)
0 18 of 136 (13⋅2) 35 of 179 (19⋅6) 1 of 10 (10) −0⋅17
1 55 of 136 (40⋅4) 63 of 179 (35⋅2) 5 of 10 (50) 0⋅11
2 47 of 136 (34⋅6) 59 of 179 (33⋅0) 2 of 10 (20) 0⋅03
3 15 of 136 (11⋅0) 20 of 179 (11⋅2) 1 of 10 (10) −0⋅005
4 1 of 136 (0⋅7) 2 of 179 (1⋅1) 1 of 10 (10) −0⋅04
No. of Hardman factors (imputed)
0 46 (14⋅4) 89 (20⋅5) 5 (12) −0⋅16
1 137 (42⋅9) 175 (40⋅2) 18 (44) 0⋅06
2 105 (32⋅9) 140 (32⋅2) 15 (37) 0⋅02
3 30 (9⋅4) 28 (6⋅4) 2 (5) 0⋅11
4 1 (0⋅3) 3 (0⋅7) 1 (2) −0⋅05
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.) with data missing for one patient in the general anaesthesia (GA)
group. LA, local anaesthesia; RA, regional anaesthesia; MD, mean difference; AAA, abdominal aortic aneurysm.
data are summarized as a number and percentage. Patients
undergoing EVAR were grouped by the type of anaesthe-
sia received: LA, GA or RA. Standardized mean differences
were calculated to quantify the differences between base-
line characteristics and the aortic morphology of patients
undergoing EVAR under GA and LA.
Cox proportional hazards regression was used to com-
pare in-hospital mortality by mode of anaesthesia. Sur-
vivors were censored at hospital discharge. The analysis
was adjusted for modified Hardman index13, ASA fitness
grade, maximum AAA diameter and sex, and centre fitted
as a frailty term. Kaplan–Meier curves were constructed
to estimate mortality rates to 30 days. Secondary outcomes
are described, but not compared formally. For duration of
ICU and hospital stay, patients who died before hospital
discharge were censored at death.
Missing data are described in table footnotes. Multiple
imputationwas used to account formissing data in analyses.
Fifty-two imputed data sets were generated and the results
combined using Rubin’s rules14. Sensitivity analyses with
missing data items for the Hardman index were assigned 0
points (sensitivity analysis 1) or 1 point (sensitivity analysis
2). All analyses were performed in Stata® version 15.1
(StataCorp, College Station, Texas, USA).
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Results
Between January 2014 and December 2016, the NVR
collected data on 20 936 patients undergoing AAA repair,
13 354 (63⋅8 per cent) of whom underwent EVAR. Of these
13 354 patients, 795 (6⋅0 per cent) had rEVAR (Fig. 1). The
majority of patients undergoing rEVAR received GA (435,
54⋅7 per cent), with 319 (40⋅1 per cent) having LA and 41
(5⋅2 per cent) RA.
rEVAR procedures were carried out across 72 hospitals,
56 (78 per cent) of which performed at least one proce-
dure under LA. The hospitals that used LA for rEVAR
were the higher-volume centres carrying out a median of
47⋅0 EVAR and 15⋅2 rAAA procedures each year, com-
pared with a median of 26⋅7 EVAR and 7⋅9 rAAA pro-
cedures in the non-LA centres (Fig. 2a; Table S1, sup-
porting information). Across the 56 centres performing
rEVAR under LA, a median of 40⋅0 (i.q.r. 22⋅6–60⋅0)
per cent of procedures used LA, and the rate was sim-
ilar for procedures performed during standard working
hours (08.00 to 17.00 hours Monday to Friday) and proce-
dures performed out of hours (Fig. 2b; Table S2, supporting
information).
Patient characteristics
Mean age was 79 years in the LA and RA groups and
77 years in theGA group; themajority of patients weremen
(Table 1). Over 85 per cent of patients had co-morbidities
and 15 per cent were moribund (ASA grade V). Of patients
with data, only 16⋅6 per cent had none of the four risk fac-
tors included in the modified Hardman index, and 12⋅3 per
cent had at least three risk factors. The mean maximum
AAA diameter exceeded 72mm in all groups. Characteris-
tics of patients in the LA and GA groups were similar, as
indicated by the small mean differences (less than 0⋅2) for
most factors examined.
Patients undergoing open surgery for rAAA were slightly
younger and had fewer risk factors than those having
rEVAR (Table S3, supporting information).
Outcomes
Overall, 187 of 795 patients (23⋅5 per cent) under-
going rEVAR died before hospital discharge (Table 2). The
in-hospital mortality rate was highest in the GA group,
28⋅0 per cent, followed by 18⋅5 per cent in the LA group
and 15 per cent in the RA group. After adjustment, the risk
of death in patients having rEVAR under LA was 38 per
cent lower than the risk under GA (adjusted hazard ratio
0⋅62, 95 per cent c.i. 0⋅45 to 0⋅85; P= 0⋅003).
Table 2 Postoperative outcomes following emergency
endovascular aneurysm repair
LA (n=319) GA (n=435) RA (n= 41)
Outcomes
In-hospital death 59 (18⋅5) 122 (28⋅0) 6 (15)
Postoperative
LOS (days)*†
10 (6–18) 10 (6–21) 9 (5–16)
Admitted to ICU‡ 205 of 258 (79⋅5) 262 of 329 (79⋅6) 28 of 35 (80)
Duration of ICU
stay (days)*†
2 (1–4) 3 (1–5) 2 (2–4)
Complications
Cardiac 42 of 308 (13⋅6) 69 of 409 (16⋅9) 3 (7)
Pulmonary 64 of 308 (20⋅8) 84 of 409 (20⋅5) 9 (22)
Cerebral 4 of 308 (1⋅3) 2 of 409 (0⋅5) 0 (0)
Renal failure 36 of 308 (11⋅7) 48 of 409 (11⋅7) 2 (5)
Bleeding 7 of 308 (2⋅3) 11 of 409 (2⋅7) 1 (2)
Endoleak 51 of 317 (16⋅1) 68 of 429 (15⋅9) 7 (17)
No. of
complications
0 168 of 309 (54⋅4) 235 of 417 (56⋅4) 24 (59)
1 99 of 309 (32⋅0) 115 of 417 (27⋅6) 13 (32)
2 23 of 309 (7⋅4) 35 of 417 (8⋅4) 3 (7)
3 17 of 309 (5⋅5) 31 of 417 (7⋅4) 1 (2)
4 2 of 309 (0⋅6) 1 of 417 (0⋅2) 0 (0)
Values in parentheses are percentages unless indicated otherwise; *values
are median (i.q.r.). †Estimated using survival methods with patients
censored if they died in hospital; ‡excludes patients who died in theatre.
LA, local anaesthesia; GA, general anaesthesia; RA, regional anaesthesia;
LOS, length of hospital stay.
Sensitivity analyses were consistent with the primary
analysis (Table S4, supporting information). From the
Kaplan–Meier curves, the estimated mortality rate at
30 days was 39⋅5 per cent with GA compared with 34⋅0 per
cent with LA. The risk with all three modes of anaesthesia
(GA, LA and RA) was less than the risk of death with open
repair of rAAA (Table S5, supporting information).
Almost 80 per cent of patients were admitted to ICU.The
median length of stay was 2 days, and median postoperative
hospital stay was 10 days in both the GA and LA groups.
The complication rates were also similar in the two groups:
168 of 309 patients (54⋅4 per cent) in the LA group had no
reported complications compared with 235 of 417 (56⋅4 per
cent) in the GA group (Table 2).
Discussion
The main finding of this contemporary UK-based study is
that LA for endovascular repair of rAAA is associated with
reduced in-hospital mortality compared with GA.
Four RCTs4–7 comparing open and endovascular repair
have reported broadly comparable outcomes between the
two approaches, and EVAR is now an established treatment
strategy for rAAA. This has led to the emergence of rAAA
repair under LA and RA that was previously not possible
© 2018 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS
on behalf of BJS Society Ltd.
R. Mouton, C. A. Rogers, R. A. Harris and R. J. Hinchliffe
during open surgery. The observed benefit of LA in terms
of reduced in-hospital mortality is in line with that reported
in the IMPROVE study9, which showed an adjusted four-
fold reduction in 30-day mortality among patients treated
under LA: odds ratio 0⋅27, 95 per cent c.i. 0⋅10 to 0⋅70
(P= 0⋅007). A recent retrospective analysis of the National
Surgical Quality Improvement Program (NSQIP)15 as well
as the Vascular Quality Initiative (VQI)16 databases also
showed a significantly reduced risk-adjusted 30-day mor-
tality rate for patients who had emergency EVAR under LA
compared with GA in the USA. According to these reports,
the use of LA as mode of anaesthesia for emergency EVAR
in the USA is less common (9⋅4 per cent in NSQIP and
12⋅2 per cent in VQI)15,16 than in the present UK cohort,
where 40⋅1 per cent of patients treated for rAAA with an
endovascular strategy were treated under LA. UK vascular
surgeons appear to have adopted the LA approach more
rapidly than their colleagues in the USA. This might be
a direct result of the IMPROVE trial9. The present find-
ing of similar baseline characteristics between the LA and
GA groups is in contrast to previous observational stud-
ies on elective aneurysm repair where patients undergoing
elective EVAR under LA or RA tended to be older, with
a higher ASA grade and a greater burden of cardiopul-
monary co-morbidity comparedwith patients who received
GA17–21.
This study provides information on selection criteria
and outcomes relating to the mode of anaesthesia for
emergency EVAR in a real-world setting in the UK. Some
78 per cent of vascular centres offered surgery under LA.
Furthermore, the use of LA for rEVAR was not affected
by the timing of the surgery; vascular units with a higher
volume of aortic surgery were more likely to offer LA
for rEVAR. These are important service delivery issues.
The choice of anaesthesia in this registry analysis did not
seem to be influenced by known patient characteristics,
cardiovascular risk factors, ASA grade or aortic diameter.
The reasons why vascular surgeons and anaesthetists opt
for either LA or GA in specific situations are not evident,
and this needs further exploration. Although the mode
of anaesthesia used for emergency EVAR appears to be
important, the results of the present study do not offer
an explanation for the observed benefit of LA. Theories
about the potential causes of poorer outcomes with GA
include relaxation of tissues and release of tamponade, and
the significant haemodynamic effects of GA, including loss
of vascular tone, all of whichmay be exacerbated in patients
with rAAA experiencing shock22.
Any registry is limited by the completeness and qual-
ity of its data. The NVR is externally validated against
HES data in England (and equivalent routine data for
Scotland, Wales and Northern Ireland), and any discrep-
ancies are raised at a central level. Case ascertainment
rates continue to improve; over the 3 years from 2014 to
2016 it was 91 per cent for rAAA12. Nevertheless, the
observed mortality rate was lower than might be expected
for this patient group, and the potential for reporting bias
remains. The NVR data collection system includes exten-
sive checks to ensure that the values entered are valid (range
checks and cross-validation on various fields), and individ-
ual hospitals are asked to check data that appear spurious.
Thus the internal validity of the registry is high. Addition-
ally, multiple imputation methods were applied to ensure
all cases were included in the analyses and not dropped
owing to missing data. The NVR was established as part
of the National Clinical Audit and Patient Outcomes Pro-
gramme, and was not designed primarily for research10.
Despite its limitations, registries such as the NVR are a
vital tool to audit the safety of novel treatment approaches
in rAAA and to monitor that trial outcomes are being repli-
cated in routine practice.
Emergency EVAR can be undertaken under different
modes of anaesthesia. However, there is a lack of standard-
ization and consistency in how anaesthetic techniques are
defined23. The complexity increases when sedation is used
alongside LA or RA. The recording of anaesthesia in the
NVR does not include whether or not sedation was used.
The boundary between deep sedation and GA is fluid, and
both definitions can include patients whose airway and ven-
tilatory function might require support24. It is not known
how many of the procedures in the present study cohort
from the NVR were started as an LA procedure and con-
verted to GA. This may introduce bias and is a potential
weakness that was not possible to address due to the limita-
tions of the database. In the IMPROVE trial, 16 per cent of
patients treated initially under LA were converted to GA,
and the outcomes of this group were similar to those of the
GA group9. There are other potential confounders that this
study could not address as the data were not available. For
example, the level of haemodynamic instability may affect
both the choice of anaesthesia and outcomes. If the propor-
tion of more haemodynamically stable patients was higher
in the LA group this would favour LA. Furthermore, cen-
tres using LA had higher case volumes than those not using
LA, and theremight be unknown centre-specific character-
istics such as experience of LA and secondary transfers that
could influence outcome.
Mortality from emergency surgery for rAAA remains
high, with variation among different healthcare systems
and countries. Furthermore, the burden of morbidity is
significant in survivors. Therefore, even a small reduction
in perioperative mortality could have a dramatic effect.
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This study provides further evidence of the benefit of LA
for patients undergoing emergency EVAR for rAAA.
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